A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral …

A Wolff, RK Joshi, J Ekström, D Aframian… - Drugs in R&d, 2017 - Springer
Background Medication-induced salivary gland dysfunction (MISGD), xerostomia (sensation
of oral dryness), and subjective sialorrhea cause significant morbidity and impair quality of …

Sex differences in the psychopharmacological treatment of depression

JJ Sramek, MF Murphy, NR Cutler - Dialogues in clinical …, 2016 - Taylor & Francis
Although a number of studies have observed that females respond better to serotonergic
antidepressants than males and that postmenopausal females have a diminished response …

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

RR Jones, MP Freeman, SG Kornstein… - Archives of Women's …, 2022 - Springer
The objective of this analysis was to determine if there are sex differences with esketamine
for treatment-resistant depression (TRD). Post hoc analyses of three randomized, controlled …

Sex differences in pharmacokinetics of antidepressants

N Kokras, C Dalla… - Expert opinion on drug …, 2011 - Taylor & Francis
Introduction: Sex differences have been identified in antidepressant treatment; however, it
remains unclear to what extent pharmacokinetics contributes to these differences. As current …

Predictors of treatment response to pharmacotherapy in patients with persistent postural–perceptual dizziness

S Min, JS Kim, HY Park - Journal of Neurology, 2021 - Springer
The study aimed to identify the predictors of response to selective serotonin reuptake
inhibitors (SSRIs) for 12 weeks in patients with persistent postural–perceptual dizziness …

Advances in pharmacotherapy of late-life depression

JL Beyer, KG Johnson - Current psychiatry reports, 2018 - Springer
Abstract Purpose of Summary This paper reviews recent research on late-life depression
(LLD) pharmacotherapy, focusing on updated information for monotherapy and …

Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study

J Zhou, X Wang, L Feng, L Xiao, R Yang, X Zhu, H Shi… - BMC psychiatry, 2021 - Springer
Background In the population of postmenopausal patients with major depressive disorder
(MDD), the superiority of serotonin-norepinephrine reuptake inhibitors (SNRIs) over …

Desvenlafaxine in the treatment of major depression: an updated overview

TR Norman, JS Olver - Expert opinion on pharmacotherapy, 2021 - Taylor & Francis
Introduction: Major depressive disorder (MDD) remains one of the most prevalent mental
health conditions. It is a chronic, relapsing condition and despite multiple treatment options …

Women's psychiatry

G Balta, C Dalla, N Kokras - Frontiers in Psychiatry: Artificial Intelligence …, 2019 - Springer
Brain disorders and mental diseases, in particular, are common and considered as a top
global health challenge for the twenty-first century. Interestingly, women suffer more …

Desvenlafaxine for the treatment of major depressive disorder

SG Kornstein, RS McIntyre, ME Thase… - Expert opinion on …, 2014 - Taylor & Francis
Introduction: Major depressive disorder (MDD) is a chronic and debilitating condition often
characterized by inadequate treatment. Notwithstanding the availability of more than a …